Merck Nears Over $3.3 Billion Deal to Acquire Cidara Therapeutics for Late-Stage Antiviral Candidate CD388

(Source: Yidu Pharma)

Source: Yidu Medicine

According to Reuters citing the Financial Times11Month13Reported on the day,MSD Is Close to Reaching a Deal to Acquire Biotech CompanyCidara Therapeutics(Stock Code:CDTX.O). This transaction is forCidaraThe valuation will be higher than its current33Billion-dollar market capitalization,If everything goes smoothly, the official announcement could be made as early as this Friday (unless there are any last-minute unforeseen circumstances).

The report cited sources as saying that, as of11Month13On the evening of the day, MSD still needs to compete with another pharmaceutical company for the acquisition.CidaraQualifications, finalCidaraChose MSD's acquisition plan.

The specific price of the current transaction has not been disclosed, but reports indicate that this acquisition will most likely adopt“Cash+Milestone Payment”The combination method, milestone payments will be associated withCidaraRelevant drugs achieve clinical trial objectives.

Regarding the acquisition rumors,CidaraThe party has clearly refused to comment, and MSD has not immediately responded to related inquiries.

One of the core reasons why this acquisition has drawn so much attention isCidaraA key drug under developmentCD388. Just last month,FDAGrantedCD388“Breakthrough Therapy”It is recognized that this drug is mainly used to prevent high-risk populations from contracting influenza A and B.

“Breakthrough Therapy”Identified asFDAA special channel established to accelerate the research, development, and review of drugs for severe diseases or unmet medical needs. This designation not only highlightsCD388The clinical value in the field of influenza prevention has also provided important endorsement for its subsequent research and development process and market potential, becoming a key highlight contested by pharmaceutical giants such as MSD.

If this acquisition is successfully completed, it will further enrich MSD's pipeline layout in the anti-infective field.Cidara's innovative drug R&D capabilities will also achieve faster transformation with the help of MSD's resource advantages, bringing new treatment options for influenza prevention in high-risk populations globally. The specific terms of subsequent transactions andCD388The development advancement plan awaits further disclosure from both parties' official sources.